Recombinant shingles vaccine linked to lower risk of dementia
After the introduction of a shingles vaccine (Zostavax) in 2006, several studies suggested that the risk of dementia might be lower in people who had received the vaccine, although the results were inconclusive. In many countries Zostavax has been withdrawn and replaced by a much more effective vaccine (Shingrix). A study published today in Nature Medicine suggests that this new recombinant shingles vaccine, Shingrix, is associated with a greater reduction in the risk of dementia compared to Zostavax and vaccines against other types of infections.